ES2168772T3 - Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina. - Google Patents

Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.

Info

Publication number
ES2168772T3
ES2168772T3 ES98932685T ES98932685T ES2168772T3 ES 2168772 T3 ES2168772 T3 ES 2168772T3 ES 98932685 T ES98932685 T ES 98932685T ES 98932685 T ES98932685 T ES 98932685T ES 2168772 T3 ES2168772 T3 ES 2168772T3
Authority
ES
Spain
Prior art keywords
insulin
hormone
growth
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98932685T
Other languages
English (en)
Inventor
Thomas Olin
Christina Reuterdahl
Axel Stahlbom
Antek Wielburski
Harriet Ronnholm
Stephen James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702595A external-priority patent/SE9702595D0/xx
Priority claimed from SE9802023A external-priority patent/SE9802023D0/xx
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of ES2168772T3 publication Critical patent/ES2168772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Uso de una dosis eficaz de hormona de crecimiento humana en la preparación de un agente para el tratamiento de un paciente cuyo corazón presenta resistencia a la insulina o está en riesgo de adquirir dicha resistencia.
ES98932685T 1997-07-04 1998-06-26 Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina. Expired - Lifetime ES2168772T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702595A SE9702595D0 (sv) 1997-07-04 1997-07-04 new therapeutic use
SE9802023A SE9802023D0 (sv) 1998-06-08 1998-06-08 New therapeutic use

Publications (1)

Publication Number Publication Date
ES2168772T3 true ES2168772T3 (es) 2002-06-16

Family

ID=26663028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98932685T Expired - Lifetime ES2168772T3 (es) 1997-07-04 1998-06-26 Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.

Country Status (12)

Country Link
EP (1) EP1007085B1 (es)
JP (1) JP2002511876A (es)
AT (1) ATE209042T1 (es)
AU (1) AU737065B2 (es)
CA (1) CA2294824A1 (es)
DE (1) DE69803298T2 (es)
DK (1) DK1007085T3 (es)
ES (1) ES2168772T3 (es)
NO (1) NO20000007L (es)
NZ (1) NZ501961A (es)
PT (1) PT1007085E (es)
WO (1) WO1999001151A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064062A1 (en) * 1998-06-08 1999-12-16 Pharmacia & Upjohn Ab New therapeutic use of pkb (proteine kinase b) enhancers
SE9901634D0 (sv) * 1999-05-05 1999-05-05 Sahltech Ab Treatment of myocardial infarction with a substance related to the growth hormone axis
AU2006200127B2 (en) * 2000-03-13 2007-10-25 Pfizer Inc. Use of growth hormone in low dose
SE0000837D0 (sv) * 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
WO2008027854A2 (en) * 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
JPH09501533A (ja) * 1994-04-18 1997-02-10 ガイ フレール バーント エ エクスポルタシオン ソシエテ アノニム 物体用電子メモリ素子
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
SE9601397D0 (sv) * 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone

Also Published As

Publication number Publication date
NO20000007L (no) 2000-03-06
ATE209042T1 (de) 2001-12-15
DE69803298T2 (de) 2002-08-08
NO20000007D0 (no) 2000-01-03
WO1999001151A1 (en) 1999-01-14
DK1007085T3 (da) 2002-05-13
PT1007085E (pt) 2002-05-31
AU8250698A (en) 1999-01-25
JP2002511876A (ja) 2002-04-16
DE69803298D1 (de) 2002-02-21
AU737065B2 (en) 2001-08-09
EP1007085B1 (en) 2001-11-21
EP1007085A1 (en) 2000-06-14
NZ501961A (en) 2001-11-30
CA2294824A1 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69836352D1 (de) Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
SE8802569D0 (sv) Improvements in or relation to somatostatins
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
ID24184A (id) Obat untuk perawatan disfungsi ereksi
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
GR3032224T3 (en) Therapeutic agent for threatened abortion.
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
MD1469G2 (ro) Metodă de tratament al şocului combustional
RU95122262A (ru) Способ лечения повреждений периферических нервов при травмах конечностей

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1007085

Country of ref document: ES